Umer Raffat analyst EVERCORE

Currently out of the existing stock ratings of Umer Raffat, 10 are a BUY (76.92%), 1 are a SELL (7.69%), 2 are a HOLD (15.38%).

Umer Raffat

Work Performance Price Targets & Ratings Chart

Analyst Umer Raffat, currently employed at EVERCORE, carries an average stock price target met ratio of 16.67% that have a potential upside of 4.11% achieved within 22 days.

Umer Raffat’s has documented 21 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ALKS, Alkermes Plc at 24-Oct-2023.

Wall Street Analyst Umer Raffat

Analyst best performing recommendations are on ALKS (ALKERMES PLC).
The best stock recommendation documented was for ALKS (ALKERMES PLC) at 6/9/2016. The price target of $59 was fulfilled within 154 days with a profit of $15.18 (34.64%) receiving and performance score of 2.25.

Average potential price target upside

OGN Organon AMLX Amylyx Pharmaceuticals ALKS Alkermes Plc CELG Celgene MYL Viatris PHAT Phathom Pharmaceuticals VTRS Viatris AGN Allergan plc AMGN Amgen MDCO The Medicines Company GILD Gilead Sciences RPRX Royalty Pharma Plc TEVA Teva Pharma Industries Ltd ADR CERE Cerevel Therapeutics Holdings

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$20

$5.42 (37.17%)

$18

7 months 19 days ago
(06-May-2024)

4/5 (80%)

$-0.68 (-3.29%)

75

Buy

$24

$9.42 (64.61%)

$22

7 months 26 days ago
(29-Apr-2024)

2/5 (40%)

$5.45 (29.38%)

196

Hold

$22

$7.42 (50.89%)

$27

1 years 2 months 14 days ago
(11-Oct-2023)

5/8 (62.5%)

$5.46 (33.01%)

145

Hold

1 years 4 months 25 days ago
(31-Jul-2023)

0/1 (0%)

$8.93 (30.72%)

Buy

$33

$15.64 (90.09%)

1 years 9 months 10 days ago
(16-Mar-2023)

0/1 (0%)

$11.28 (51.93%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Umer Raffat?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?